Management of Hemophilia under Limited Resources

Size: px
Start display at page:

Download "Management of Hemophilia under Limited Resources"

Transcription

1 Management of Hemophilia under Limited Resources Ampaiwan Chuansumrit, M.D. ISTH Advanced Training Course International Hemophilia Training Center-Bangkok Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

2 Disclosures for In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board No relevant conflicts of interest to declare No relevant conflicts of interest to declare No relevant conflicts of interest to declare No relevant conflicts of interest to declare Novo Nordisk, Shire, Roche Novo Nordisk, Shire, Roche Novo Nordisk, Shire, Roche Presentation includes discussion of the following off-label use of a drug or medical device: <N/A>

3 Integration of Hemophilia into the Existing Infrastructure University hospital Regional hospital Provincial hospital District hospital Health station Super specialized care Complicated cases 3 o medical care 3 o hemophilia care 2 o medical care 2 o hemophilia care 1 o medical care 1 o hemophilia care 1 o health care home care treatment

4 Replacement Therapy for Thai Hemophilia Western Countries Thailand Whole blood Plasma Cryoprecipitate & FFP Intermediate purity factor concentrate Virus inactivated high purity factor concentrate First generation recombinant factor concentrate Second to third generation recombinant factor concentrate

5 Laboratory Diagnosis of Hemophilia A & B Prolonged APTT Low level of FVIII:C or FIX:C Bedside diagnostic kit - First version published in Haemophilia 2009;15: WB WB +FVIII WB +FIX - Second version published in Haemophilia 2013;19:e48-e49.

6 Important Issues Provide knowledge to patients and parents Effective bleeding prevention through daily life-style should be emphasized

7 First Aid Management for Bleeding Episode R = Rest I = Ice C = Compression E = Elevation

8 Healthy Diet Healthy diet is important, not to gain too much weight that will burden the joint function and create difficulty in venipuncture

9 Hereditary Bleeding Disorder ว on 3 Jan 2007

10 Replacement Therapy Heat-Treated Lyophilized Cryoppt

11 Replacement Therapy Episodic bleeding treated in the hospital Early bleeding treated at home, nearby health stations or hospitals Prophylactic treatment

12 Treatment Guideline Type of bleeding Initial Level of factor (%) Maintenance 1. Bleeding at muscle, suture wound, dental procedure* Deep hematoma, hemarthrosis, large wound (3-7 days) 3. Bleeding in vital organs, CNS, GI, ileopsoas muscle, and general surgery e.g. appendectomy (1 week) 4. Major surgery of musculoskeletal, brain surgery (1-3 weeks) *In case of using fibrin splint, replacement therapy may not be needed

13 Continuous Infusion Chuansumrit A, et al. Thai J Hematol Transf Med 1998;8:25-31.

14 Dental Splint

15 Fibrinogen + Thrombin Fibrin Glue - to treat superficial wound - to prevent bleeding in - dental extraction, surgery

16 Replacement Therapy Episodic bleeding treated in the hospital Early bleeding treated at home, nearby health stations or hospitals Prophylactic treatment

17 Early Treatment At the first sign of tingling sensation associated with early bleeding into muscles or joints Immediate after trauma When treatment is given early, less blood product was used and less further bleeding occurs compared to delayed treatment

18 Process Mapping of Treating Early Bleeding Intervention Morbidity Suffering from pain Transfusiontransmitted diseases IPD h before receiving blood components Significant bleeding Transport to hospital ER / OPD Receiving blood component: cryoppt, FFP 3-7d 3-12 h 1-3 h 6-12 h Register at Hemophilia Comprehensive Care Center Early bleeding episode Infusing factor concentrate at home/nearby hospital min Hospitalized 3-7 d - Absence from work &school - Direct cost: IPD - Indirect cost

19 Case Study from Ramathibodi Hospital Parents provide proper care to prevent bleeding episodes Provide early bleeding treatment at home, nearby health stations or hospitals 1-10 years 250 units every 7 days years 500 units every 10 days years 500 units every 15 days Hospitalization 1-15 years 3 hospitalizations per year years 2 hospitalizations per year

20 Patients and Parents Exercise to have prominent vein Select the venipuncture site and remove the needle while hospitalized Practice venipuncture on a model and real vein

21 Exercise to Have Prominent Vein

22 Simple Tool for Practicing Venipuncture

23 Practice Venipuncture in the Hospital

24 Benefit of Early Treatment among Thai Hemophilia First decade Second decade Third decade Number of patients Number of patients receiving home treatment Number of patients with unaided proper walking 15 (31.9%) 30 (51.7%) 40 (67.8%) 27 (62.8%) 43 (75.4%) 49 (84.5%) Proportion of deaths 14 (29.8%) 8 (13.8%) 3 (5.1%) Chuansumrit A, et al. Haemophilia 2004;10:542-9.

25 Nationwide Coverage of Hemophilia Starting 2009 Set up a hemophilia / hematology clinic A limited budget to purchase factor concentrate for treating early bleeding episode A limited budget to treat life-threatening bleeding episodes or emergency surgery Patient has to conduct self-care to avoid bleeding

26 Dose of Factor VIII / Factor IX Children less than 10 years of age received 250 units of factor VIII concentrate weekly Age 1 yr, BW 10 kg, 25 units/kg Age 3 yr, BW 14 kg, 18 units/kg Age 5 yr, BW 18 kg, 14 units/kg Age 7 yr, BW 22 kg, 11 units/kg Age 9 yr, BW 26 kg, 10 units/kg

27 Nationwide Coverage of Hemophilia Starting hospitals participate to the registration with a total of 1,519 patients Empty bottle of factor concentrate Provided factor concentrate

28 24-Hour Hotline Consultation International Hemophilia Training Center-Bangkok

29 Hemophilia Day Started April, 1995

30 Short Course Training for Medical Personnel Nov, 2009 Chiang Rai Regional Hospital Jul, 2006 Chiang Mai University Hospital Apr, 2007 Khon Kaen University Hospital Aug, 2011 Sawanpracharak Regional Hospital Nov, 2011 Sappasitprasong Regional Hospital Jan, 2008 Ratchaburi Regional Hospital Feb, Saraburi Regional Hospital - Thammasat University Hospital - Srinakarinviroj University Hospital May, 2008 Nakhon Si Thammarat Regional Hospital

31 Comparison between Before and After Receiving Factor Concentrate for Treating Early Bleeding Before After Total episodes of hospitalization * Episodes of hospitalization/case * +2.4 Total days of hospitalization 3,230 1,724* Days of hospitalization/case * Days of hospitalization/bleed * *P < Sooksriwong C, et al. Haemophilia 2012;18:e347-e363.

32 Comparison between Two Policies Severity Policy Life time cost of QALY Cost per ICER treatment (THB) QALY Mild No home base care 4,998, ,595 Home base care 5,225, ,103 80,542 Moderate No home base care 13,659, ,504 Home base care 11,198, ,157 Cost saving Severe No home base care 25,908, ,122,085 Home base care 20,189, ,557 Cost saving Pattanaprateep O, et al. VIHRI 2014;3C:37-38.

33 Replacement Therapy Episodic bleeding treated in the hospital Early bleeding treated at home, nearby health stations or hospitals Prophylactic treatment - single dose prophylaxis - secondary prophylaxis for 1-3 months - long term prophylaxis

34 Prophylactic Treatment Standard dose of prophylaxis units/kg three times per week for hemophilia A and twice a week for hemophilia B Escalated regimen of 50 units/kg once a week, 30 units/kg twice a week and 25 units/kg three times per week Low dose prophylaxis of 8-10 units/kg twice weekly* or daily 5 units/kg *Chuansumrit A, et al. Southeast Asian J Trop Med Public Health 1995;26(2):

35 Adult Hemophilia with Morbidity Chronic synovitis induces frequent bleeding and pain Deformity of the musculoskeletal requiring corrective orthopedic surgeries and rehabilitation - Large amount of virus-inactivated factor concentrate - Prosthesis: hip, knee month prophylaxis for preserving the replaced joint and act as low dose immune tolerance

36 Teaching Material for Genetic Counseling

37 Carrier Detection & Prenatal Diagnosis 1988 Carrier detection by assaying FVIII:C, FIX:C, VWF:Ag 1991 Addition of DNA analysis 1994 Prenatal diagnosis for females at risk of having a hemophiliac son with severe and moderate degrees - Chorionic villus sampling for weeks of gestation - Amniocentesis for weeks of gestation - Cordocentesis for weeks of gestation Chuansumrit A, et al. Haemophilia 2016;880-5.

38 Hemophilia with Inhibitor The most problematic complication Difficulty in effective bleeding control Higher treatment costs Increased morbidity and mortality Prevalence of factor VIII inhibitor 25-30% of patients with severe hemophilia A Prevalence of factor IX inhibitor 2-3% of patients with hemophilia B

39 Bonn Protocol of ITI Factor VIII concentrate 100 u/kg bid FEIBA u/kg bid when inhibitor <1 BU Factor VIII concentrate 150 u/kg bid Brackmann HH, et al. Vox Sang 1996;70(Suppl):30-5.

40 Important Predictors of Successful ITI Low pre ITI inhibitor titer <10 BU Low peak historical inhibitor titer <200 BU Low peak inhibitor during ITI < BU Short duration between the onset of inhibitor and start of ITI <1-2 years Low risk factor VIII gene: small insertion, small deletion, missense mutations

41 Immune Tolerance Induction Lyophilized cryoprecipitate 13 units/kg 3 times/week Inhibitor (BU/mL) Weeks Heat treated lyophilized cryoprecipitate Chuansumrit A, et al. Haemophilia 2000;6:523-5.

42 Dose of Factor VIII Plasma-derived factor VIII concentrate 100 units/kg 3 times/wk for 6 months 50 units/kg 3 times/wk for 6 months 50 units/kg 1-2 times/wk for 1 year

43 FVIII:C (BU) Immune Tolerance Induction Factor VIII conc 50 u/kg x 2/wk PCC 50 u/kg x 2/wk 100 u/kg x 3/wk 50 u/kg x 3/wk 70 u/kg x 2/wk Week

44 Successful ITI Negative inhibitor (<0.6 BU) Normalized FVIII recovery >66% FVIII:C half life >6 h after 72 h washout period

45 Inhibitor to Factor VIII Clotting Activity 4500 Episodic treatment Immune tolerance 2 nd Prophylaxis Inhibitors (BU) Age (Years)

46 46

47 Plasma Fractionation Centre National Blood Centre, Thai Red Cross Society

48 Plasma Fractionation Centre National Blood Centre, Thai Red Cross Society

49 Thank You for Your Attention

Management of Hemophilia under Limited Resources

Management of Hemophilia under Limited Resources Management of Hemophilia under Limited Resources Ampaiwan Chuansumrit, M.D. International Hemophilia Training Center-Bangkok Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

More information

Perspective Management of Hemophilia: Past, Present & Future Ampaiwan Chuansumrit, M.D.

Perspective Management of Hemophilia: Past, Present & Future Ampaiwan Chuansumrit, M.D. Perspective Management of Hemophilia: Past, Present & Future Ampaiwan Chuansumrit, M.D. International Hemophilia Training Center-Bangkok Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok,

More information

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018 Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested

More information

Prior Authorization Criteria Hemophilia/Blood Factor Products

Prior Authorization Criteria Hemophilia/Blood Factor Products Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness

More information

70% not diagnosed, 75% not treated Many die in childhood or grow-up severely disabled

70% not diagnosed, 75% not treated Many die in childhood or grow-up severely disabled Economic Reality and the Development of Haemophilia Care Brian O Mahony, CEO Irish Haemophilia Society Esfahan, Iran April 2009 1 Haemophilia Care Globally 70% not diagnosed, 75% not treated Many die in

More information

Congenital Fibrinogen Deficiency. Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1

Congenital Fibrinogen Deficiency. Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1 Congenital Fibrinogen Deficiency Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1 claude.negrier@chu-lyon.fr Afibrinogenaemia Clinical presentation Phenotypic and genotypic

More information

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary

More information

A Patient-Centered Approach to Understanding the Burden of Inhibitors

A Patient-Centered Approach to Understanding the Burden of Inhibitors A Patient-Centered Approach to Understanding the Burden of Inhibitors Mark W. Skinner, JD FDA-CERSI Collaborative Workshop on Predictive Immunogenicity for Better Clinical Outcomes 3-4 Oct 2018 Washington,

More information

EVOLUTION OF INHIBITOR TREATMENT

EVOLUTION OF INHIBITOR TREATMENT EVOLUTION OF INHIBITOR TREATMENT Flora Peyvandi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico and University of Milan, Italy February

More information

What We Know 3/27/2014. Hemophilia Federation of America Symposium Inhibitor Track. Developed by Sue Geraghty, R.N. 1

What We Know 3/27/2014. Hemophilia Federation of America Symposium Inhibitor Track. Developed by Sue Geraghty, R.N. 1 Out of Control: What Sends an Inhibitor into Overdrive? Sue Geraghty, RN, MBA Retired Nurse Coordinator University of Colorado Denver HTC March 27, 2014 What We Know Inhibitors occur in approximately 30%

More information

How to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course

How to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course How to Approach a Patient with Bleeding Nigel Key MB ChB FRCP November 1, 2016 Disclosures for Nigel Key In compliance with COI policy, ISTH requires the following disclosures to the session audience:

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hemlibra (emicizumab-kxwh) Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hemlibra (emicizumab-kxwh) Prime Therapeutics will review Prior Authorization

More information

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Personalized hemophilia treatment Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Evolution of Hemophilia

More information

Current and Emerging Treatment Paradigms in the Management of Hemophilia

Current and Emerging Treatment Paradigms in the Management of Hemophilia Current and Emerging Treatment Paradigms in the Management of Hemophilia Barbara A. Konkle, MD Associate Director, Washington Center for Bleeding Disorders Director, Clinical and Translational Research

More information

Introduction KEY POLICY IMPLICATIONS SUMMARY A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS HEMOPHILIA A

Introduction KEY POLICY IMPLICATIONS SUMMARY A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS HEMOPHILIA A A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS APRIL 2018 Introduction HEMOPHILIA A Hemophilia A is an inherited condition that results in a deficiency in the factor VIII blood

More information

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients

More information

Thriving Amid The Turbulent Ride

Thriving Amid The Turbulent Ride Thursday, April 3 7:00 8:45 AM Rosen Shingle Creek Panzacola F 1/2 A Symposium Held in Conjunction with the 2014 NHIA Annual Conference & Exposition 2014 NHIA Annual Conference & Exposition Thriving Amid

More information

Patients Perspective in Plasma Products (Focus on Hemophilia)

Patients Perspective in Plasma Products (Focus on Hemophilia) Original Article Patients Perspective in Plasma Products (Focus on Hemophilia) Mohammad Faranoush Associate Professor, Pediatric Hematologist Oncologist, Iranian Blood Transfusion Organization Tehran,

More information

Patients Perspective in Plasma Products (Focus on Hemophilia)

Patients Perspective in Plasma Products (Focus on Hemophilia) Original Article Patients Perspective in Plasma Products (Focus on Hemophilia) Mohammad Faranoush Associate Professor, Pediatric Hematologist Oncologist, Iranian Blood Transfusion Organization Tehran,

More information

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK Drug Class Insight HEMOPHILIA Background, new developments, key strategies INTRODUCTION Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. 20,000 patients in the

More information

Cost Assessment of Implementation of Immune Tolerance Induction in Iran

Cost Assessment of Implementation of Immune Tolerance Induction in Iran VALUE IN HEALTH REGIONAL ISSUES 1 (2012) 54 58 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/vhri Cost Assessment of Implementation of Immune Tolerance Induction in

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 19 July 2007 CPMP/BPWG/1561/99 rev.1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE

More information

CONTENTS The Cost Burden of Hemophilia in Managed Care... 3 Prevalence, Drug Utilization, and Associated Costs... 3 Hemophilia is a Low Prevalence

CONTENTS The Cost Burden of Hemophilia in Managed Care... 3 Prevalence, Drug Utilization, and Associated Costs... 3 Hemophilia is a Low Prevalence CONTENTS The Cost Burden of Hemophilia in Managed Care... 3 Prevalence, Drug Utilization, and Associated Costs... 3 Hemophilia is a Low Prevalence but High Cost Disease... 3 Prescription Cost Vastly Outweighs

More information

Disclosures. Agenda 2/3/2011. Current Options and New Developments in Hemophilia. Research support to OHSU from:

Disclosures. Agenda 2/3/2011. Current Options and New Developments in Hemophilia. Research support to OHSU from: Current Options and New Developments in Hemophilia Michael Recht, MD, PhD Director, The Hemophilia Center Oregon Health and Science University Disclosures Research support to OHSU from: Baxter Pfizer NovoNordisk

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 6 No 80 ISSN 75 876 The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital Paul Harper, Mary Brasser, Louise

More information

Plasma derived medicines - the evidence for their necessity

Plasma derived medicines - the evidence for their necessity Plasma derived medicines - the evidence for their necessity FACULTY OF MEDICINE, DENTISTRY AND HEALTH SCIENCES ALBERT FARRUGIA PHD Disclosures I provide compensated services for the manufacturers of therapies

More information

Andrew Schorr: Is there anything you ve been discussing that you d like to update people about now?

Andrew Schorr: Is there anything you ve been discussing that you d like to update people about now? News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

Common Inherited Bleeding Disorders

Common Inherited Bleeding Disorders CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also

More information

Managing Patients with Hemophilia: Coordinated Care for Optimal Clinical Outcomes

Managing Patients with Hemophilia: Coordinated Care for Optimal Clinical Outcomes Managing Patients with Hemophilia: Coordinated Care for Optimal Clinical Outcomes Surabhi Palkimas, PharmD Pharmacy Clinical Coordinator, Hematology University of Virginia Health System Presentation Objectives

More information

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of

More information

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis CADTH TECHNOLOGY REVIEW Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (): Treatment Cost Comparison and Budget Impact Analysis Product Line: Technology Review Version: 1.0 Issue Number: 2 Publication

More information

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia Corporate News Baxter International Inc. One Baxter Parkway Deerfield, IL 60015 BAXTER MEDIA CONTACT: BAXTER INVESTOR RELATIONS: Marie Kennedy Mary Kay Ladone (805) 372-3543 (847) 948-3371 Doreen Eaton

More information

New Anticoagulants Linda Liu, M.D.

New Anticoagulants Linda Liu, M.D. Difficult Task New Anticoagulants Professor UCSF Dept of Anesthesia 15 minutes! Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban Relation to anesthesia Rapid reversal Regional anesthesia UC

More information

Alnylam Pharmaceuticals R&D Day. July 11, 2013

Alnylam Pharmaceuticals R&D Day. July 11, 2013 Alnylam Pharmaceuticals R&D Day July 11, 2013 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (NovoSeven RT) Reference Number: CP.PHAR.220 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center. Hemophilia A, Inhibitor, Longitudinal study

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center. Hemophilia A, Inhibitor, Longitudinal study BLOOD RESEARCH VOLUME 51 ㆍ NUMBER 1 March 2016 ORIGINAL ARTICLE Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center Ki Young Yoo, Sang Chun Joo, Yong Mook Choi

More information

Track 1: Clinical Update

Track 1: Clinical Update Challenges and Opportunities for Managing Hemophilia 2014 Track 1: Clinical Update Slide 1: Challenges and Opportunities for Managing Hemophilia Welcome to Challenges and Opportunities for Managing Hemophilia

More information

Human Protein Process Sciences, Lille, France 2. Shabrawishi Hospital Blood Bank, Cairo, Egypt 3. University of Saskatoon, Canada

Human Protein Process Sciences, Lille, France 2. Shabrawishi Hospital Blood Bank, Cairo, Egypt 3. University of Saskatoon, Canada 1 Human Protein Process Sciences, Lille, France 2 Shabrawishi Hospital Blood Bank, Cairo, Egypt 3 University of Saskatoon, Canada Why such a concept? Non-virally inactivated plasma components are still

More information

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated) Common Inherited Coagulation Disorders Bob Miller, A 2017 Inherited Coagulation Disorders Brief review of coagulation Disorders related to platelet dysfunction (not the acquired thrombocytopenias) Disorders

More information

Media Release. Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A. Basel, 17 April 2017

Media Release. Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A. Basel, 17 April 2017 Media Release Basel, 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children

More information

Hemophilia and inhibitors

Hemophilia and inhibitors Hemophilia and inhibitors What is hemophilia? You might know what Hemophilia is, but let s start from the beginning to better understand! When you get hurt and bleed, your body turns on a mechanism called

More information

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience Alfonso Iorio, MD, PhD Health Information Research Unit & Hemophilia Program

More information

Molecular diagnosis of haemophilia and other bleeding disorders

Molecular diagnosis of haemophilia and other bleeding disorders Molecular diagnosis of haemophilia and other bleeding disorders Jayandharan G Rao Associate Professor Department of Haematology Christian Medical College Vellore, India. Jayandharan et al, J Genet Synd

More information

Background, Development and Clinical Use of rfviia. Slovenian Hematology Society April 17, 2015

Background, Development and Clinical Use of rfviia. Slovenian Hematology Society April 17, 2015 Background, Development and Clinical Use of rfviia. Slovenian Hematology Society April 17, 2015 Ulla Hedner MD PhD Prof. em. University of Lund, Sweden. Key Issues in Hemophilia Treatment All bleedings

More information

Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Media Release Basel, 26 June 2017 Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful

More information

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3. Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.1; 14 Apr 2016) VI.2 VI.2.1 Elements for a Public Summary Overview of

More information

Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage

Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage Clinical Associate Professor Nolan McDonnell School of Medicine and Pharmacology, School of Women s and Infants Health University

More information

Updates in Hemophilia: Making Headway in the Multidisciplinary Setting

Updates in Hemophilia: Making Headway in the Multidisciplinary Setting Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Magdy El Ekiaby 1, Thierry Burnouf 2,3, Hadi Goubran 4, Mirjana Radosevich 5, Ahmed El Ekiaby 1. Mini-Review

Magdy El Ekiaby 1, Thierry Burnouf 2,3, Hadi Goubran 4, Mirjana Radosevich 5, Ahmed El Ekiaby 1. Mini-Review Mini-Review Page 1 of 7 Role of the mini-pool cryoprecipitate technology for cost-saving and guarantee of local Factor VIII, Von Willebrand Factor and Fibrinogen product supply: Egypt experience Magdy

More information

Le indicazioni cliniche per l utilizzo dei fattori della coagulazione

Le indicazioni cliniche per l utilizzo dei fattori della coagulazione Le indicazioni cliniche per l utilizzo dei fattori della coagulazione Elena Santagostino Centro Emofilia e Trombosi A. Bianchi Bonomi Fondazione Ca Granda, Ospedale Maggiore di Milano L'utilizzo dei medicinali

More information

Jump Starting My Research Career. Shannon L. Meeks, MD March 7, 2018

Jump Starting My Research Career. Shannon L. Meeks, MD March 7, 2018 Jump Starting My Research Career Shannon L. Meeks, MD March 7, 2018 1 Disclosures Advisory committees: CSL Behring, Bayer, Shire, Genentech, Bioverativ, HEMA Biologics and Grifols Research Support: Pfizer,

More information

Current laboratory practices in the diagnosis and management of haemophilia

Current laboratory practices in the diagnosis and management of haemophilia Current laboratory practices in the diagnosis and management of haemophilia Marc Jacquemin University of Leuven BSTH 2013 Detection of severe haemophilia A Validation of the FVIII assay for the detection

More information

PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be

PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A Pasca Samantha, Milan Marta, Sarolo Lucia,

More information

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D. Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin

More information

Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.

Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis. Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of

More information

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy ANTICOAGULANT THERAPY REVISITED 2004 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most

More information

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone #

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone # Hemophilia Product Prior Authorization Form Please complete this form in its entirety and provide relevant progress notes and/or bleeding diaries and fax to 1-888-656-0841 or call 1-800-424-7892. All lab

More information

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17 Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products

Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products 1 2 3 12 October 2017 EMA/CHMP/BPWP/144533/2009 rev. 2 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on the clinical investigation of recombinant and human plasma-derived factor

More information

Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A

Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A Media Release Basel, 20 November 2017 Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison

More information

Genetic Testing in the Clinic. Anne Goodeve Sheffield Diagnostic Genetics Service Sheffield Children s NHS Foundation Trust

Genetic Testing in the Clinic. Anne Goodeve Sheffield Diagnostic Genetics Service Sheffield Children s NHS Foundation Trust Genetic Testing in the Clinic Anne Goodeve Sheffield Diagnostic Genetics Service Sheffield Children s NHS Foundation Trust Disclosures for Anne Goodeve In compliance with COI policy, ISTH requires the

More information

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants

More information

The Role of Disease Foundations in Moving Gene Transfer Forward

The Role of Disease Foundations in Moving Gene Transfer Forward The Role of Disease Foundations in Moving Gene Transfer Forward Mark W. Skinner WFH President 7 April 2005 ASGT Stakeholder Meeting WFH Mission Introduce Improve Maintain Care for people with hemophilia

More information

WFH 2014 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

WFH 2014 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia WFH 214 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia May 15, 214 Akin Akinc, PhD Antithrombin and ALN-AT3 Program

More information

PM Concentration and Health Impacts

PM Concentration and Health Impacts PM Concentration and Health Impacts Atmospheric particles originate from a variety of sources and possess a range of physical and chemical properties. Collectively, particulate pollution is often referred

More information

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors Venkat Living Venkat with Hemophilia Living with Hemophilia The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors Tami Livnat 1, Alfica

More information

RE: Comparative Clinical Effectiveness Research Comments on S from the 110 th Congress

RE: Comparative Clinical Effectiveness Research Comments on S from the 110 th Congress March 2, 2009 The Honorable Max Baucus United States Senate Washington, DC 20510 The Honorable Kent Conrad United States Senate Washington, DC 20510 RE: Comparative Clinical Effectiveness Research Comments

More information

Hemophilia Care. Will there always be new people in the world with. Will hemophilia be treated more effectively and safely

Hemophilia Care. Will there always be new people in the world with. Will hemophilia be treated more effectively and safely Future of This chapter provides answers to these questions: Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future? Will the

More information

Introduction. Hemophilia B The Blood CME Center recently launched an Conclusion

Introduction. Hemophilia B The Blood CME Center recently launched an Conclusion TABLE OF CONTENTS Introduction Inhibitor Development Treatment Strategies HTC CME NetWorkShops : Current Issues and Trends in Hemophilia Care March 2, 2011 Introduction Hemophilia B The Blood CME Center

More information

Spark Therapeutics, Inc.

Spark Therapeutics, Inc. Spark Therapeutics, Inc. Corporate Overview August 2018 1 Forward looking statements This presentation contains "forward looking statements" within the meaning of the Private Securities Litigation Reform

More information

AT Reduction Corrects Thrombin Generation in Samples From Hemophilia A & B Patients With Inhibitors

AT Reduction Corrects Thrombin Generation in Samples From Hemophilia A & B Patients With Inhibitors AT Reduction Corrects Thrombin Generation in Samples From Hemophilia A & B Patients With Inhibitors Gili Kenet, Tami Livnat, Emma Fosbury, Pratima Chowdary, Alfica Sehgal, Akin Akinc, Benny Sorensen 1

More information

Case study: Specification of CD4+ T cell epitopes of human FVIII. Birgit Reipert Director Immunology TA Hemophilia/Hematology Baxter BioScience

Case study: Specification of CD4+ T cell epitopes of human FVIII. Birgit Reipert Director Immunology TA Hemophilia/Hematology Baxter BioScience Case study: Specification of CD4+ T cell epitopes of human FVIII Birgit Reipert Director Immunology TA Hemophilia/Hematology Baxter BioScience Mastering Immunogenicity, Boston MA, September 12-13 2011

More information

CATALYST BIOSCIENCES. Corporate Overview. 12 February 2019

CATALYST BIOSCIENCES. Corporate Overview. 12 February 2019 CATALYST BIOSCIENCES Corporate Overview 12 February 2019 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements,

More information

iccnet CHSA Clinical Protocol - HEPARIN

iccnet CHSA Clinical Protocol - HEPARIN Name: iccnet CHSA Clinical Protocol - HEPARIN This clinical guideline or clinical protocol is based on a review of best practice evidence and expert opinion. It is intended to guide practice and does not

More information

Hemophilia and Gene Therapy

Hemophilia and Gene Therapy Hemophilia and Gene Therapy Jackie Chu June 4, 2008 Overview Hemophilia, the disease Gene therapy Hemophilia as a target for gene therapy Gene delivery systems Clinical trials New methods Future of gene

More information

Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value

Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value Final Evidence Report April 16, 2018 Prepared for Institute for Clinical and Economic Review, 2018 ICER Staff David Rind, MD Chief Medical

More information

DOWNLOAD : STATISTICS OF HEMOPHILIA

DOWNLOAD : STATISTICS OF HEMOPHILIA DOWNLOAD : STATISTICS OF HEMOPHILIA DATA & STATISTICS HEMOPHILIA NCBDDD CDC hemophilia is an inherited bleeding disorder in which the blood does not clot properly. the mission of cdcâ s division of blood

More information

Gene Therapy for Hemophilia A: Are we really getting better?

Gene Therapy for Hemophilia A: Are we really getting better? Gene Therapy for Hemophilia A: Are we really getting better? XXIV Congresso Nazionale SISET Novembre 10, 2016 Abano Terme Valder R. Arruda The Children s Hospital of Philadelphia University of Pennsylvania

More information

In Hospital Bleeding Management

In Hospital Bleeding Management In Hospital Bleeding Management Geno J Merli, MD, MACP, FSVM, FHM Professor Medicine & Surgery Co-Director Jefferson Vascular Center Sidney Kimmel Medical College Thomas Jefferson University Hospitals

More information

Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852 Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable

More information

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products 21 July 2011 EMA/CHMP/BPWP/144552/2009 Committee for medicinal products for human use (CHMP) Guideline on clinical investigation of recombinant and human plasma-derived factor Draft Agreed by Blood Products

More information

Hemophilia Market Insights Understanding Hemophilia Patient Management and Reimbursement Proceedings from the 2018 AMCP Market Insights Program

Hemophilia Market Insights Understanding Hemophilia Patient Management and Reimbursement Proceedings from the 2018 AMCP Market Insights Program Hemophilia Market Insights Understanding Hemophilia Patient Management and Reimbursement Proceedings from the 2018 AMCP Market Insights Program August 14, 2018 Disclaimer Organizations may not re use material

More information

Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products

Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products 1 2 3 21 May 2015 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on core SmPC for human plasma derived and recombinant coagulation factor Draft Draft agreed by the Blood Products

More information

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research

More information

The Prophylaxis and Management of Hemophilia in Adults and Pediatrics

The Prophylaxis and Management of Hemophilia in Adults and Pediatrics Page 1 The Prophylaxis and Management of Hemophilia in Adults and Pediatrics Amber P. Lawson, Pharm.D., BCOP Hematology/Oncology Clinical Pharmacist Specialist UK HealthCare, Lexington, Kentucky This webcast

More information

New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D.

New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D. New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D. Professor of Cardiovascular Medicine University of Maryland School of Medicine Copyright A.P. Wheeler 2009

More information

Pearls and Pitfalls in Factor Inhibitor Testing

Pearls and Pitfalls in Factor Inhibitor Testing Pearls and Pitfalls in Factor Inhibitor Testing Dorothy M. Adcock M.D. Esoterix Coagulation, Laboratory Corporation of America Holdings ISLH May 19, 2015 Outline Overview of coagulation factor inhibitors

More information

Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s

Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding

More information

Gene Therapy: Fellow s Conference Fred Hutchinson Cancer Research Center. Zandra K. Klippel

Gene Therapy: Fellow s Conference Fred Hutchinson Cancer Research Center. Zandra K. Klippel Gene Therapy: Did we finally get it right? Fellow s Conference Fred Hutchinson Cancer Research Center University it of Washington Zandra K. Klippel March 2012 Introduction >6000 human diseases are monogenic

More information

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Apheresis Anticoagulant Removal Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Talk Outline Case presentation Factors associated with drug removal TPE s effects on hematologic parameters Anticoagulant properties

More information

EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK

EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK Disclosure Consultancy: CSL Behring, NovoNordisk Travel and honoraria to give lectures: Baxter, Bayer, Biogen, Biotest, Octapharma,

More information

Clotting Disorder Therapy

Clotting Disorder Therapy Last Review Date: October 13, 2017 Number: MG.MM.PH.25b Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

CATALYST BIOSCIENCES. Corporate Overview. 9 April 2019

CATALYST BIOSCIENCES. Corporate Overview. 9 April 2019 1 CATALYST BIOSCIENCES Corporate Overview 9 April 2019 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements,

More information

Future prospects for the treatment of haemophilia

Future prospects for the treatment of haemophilia Future prospects for the treatment of haemophilia Paul Giangrande Green Templeton College University of Oxford paul.giangrande@gtc.ox.ac.uk Topics to be covered: Extended half-life FVIII & IX products

More information

Media Release. CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors

Media Release. CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors Media Release CHMP recommends EU approval of Roche s Hemlibra for people with severe haemophilia A without factor VIII inhibitors First medicine to significantly reduce treated bleeds compared to prior

More information

Update on the Direct Oral Anticoagulants (DOACs)

Update on the Direct Oral Anticoagulants (DOACs) Update on the Direct Oral Anticoagulants (DOACs) J. Randle Adair DO, PhD Internal Medicine New Mexico Cancer Center & Co-Chair, Anticoagulation Subcommittee Presbyterian Healthcare Services (PHS) Attending,

More information

Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan

Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan Original Article http://dx.doi.org/10.3349/ymj.2013.54.2.358 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(2):358-365, 2013 Economic Burden of High-Responding Inhibitors in Patients with Hemophilia

More information

Cost of Illness Patients with Hemophiliain RSUP Dr. Sardjito Yogyakarta

Cost of Illness Patients with Hemophiliain RSUP Dr. Sardjito Yogyakarta Research Article Cost of Illness Patients with Hemophiliain RSUP Dr. Sardjito Yogyakarta Umi Nafisah 1, Satibi 2*, DiahAyu Puspandari 3 1) Student at Magister Management Faculty of Pharmacy, UniversitasGadjahMada,

More information

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep Mark Crowther on behalf many Some slides modified from other sources 1 Disclosures Major disclosure: Paid consulting with Portola,

More information